Hafnium oxide
- Generic Name
- Hafnium oxide
- Drug Type
- Small Molecule
- Chemical Formula
- HfO2
- CAS Number
- 12055-23-1
- Unique Ingredient Identifier
- 3C4Z4KG52T
Nanobiotix's Radioenhancer JNJ-1900 Enters Phase 2 Trial for Unresectable NSCLC
• Nanobiotix has dosed the first patient in the CONVERGE study, a Phase 2 trial evaluating JNJ-1900 (NBTXR3) for Stage 3 unresectable non-small cell lung cancer.
• The CONVERGE trial, sponsored by Janssen, assesses JNJ-1900 in combination with chemoradiation and durvalumab for patients with advanced NSCLC.
• JNJ-1900, a novel radioenhancer, aims to improve tumor cell death and trigger an adaptive immune response when activated by radiotherapy.
• Nanobiotix is also evaluating JNJ-1900 in a Phase 3 trial for head and neck squamous cell cancers, with FDA Fast Track designation for HNSCC.
BioNTech Advances Oncology Pipeline with BNT327/PM8002 and mRNA Immunotherapies
• BioNTech is progressing BNT327/PM8002, a bispecific antibody, into global clinical trials for first-line small cell lung cancer and non-small cell lung cancer.
• The company plans to initiate additional trials combining BNT327/PM8002 with antibody-drug conjugates (ADCs) in 2025, expanding its combination strategy.
• BioNTech's mRNA cancer immunotherapy, autogene cevumeran, is being evaluated in a Phase 2 trial for muscle-invasive urothelial carcinoma in combination with nivolumab.
• Clinical data readouts are expected in 2025 and 2026 from multiple randomized trials of personalized and off-the-shelf mRNA cancer immunotherapy candidates.
RYBREVANT and LAZCLUZE Combination Shows Significant Survival Improvement in EGFR-Mutated NSCLC
• Johnson & Johnson's RYBREVANT plus LAZCLUZE demonstrates statistically significant and clinically meaningful improvement in overall survival (OS) versus osimertinib in EGFR-mutated NSCLC.
• The MARIPOSA Phase 3 study showed the chemotherapy-free combination is expected to improve median OS by over one year compared to the current standard of care.
• RYBREVANT plus LAZCLUZE is approved in the U.S. and Europe as a first-line therapy for NSCLC patients with EGFR exon 19 deletions or L858R substitution mutations.
• The safety profile of the combination was consistent with individual treatments, with venous thromboembolic events managed through prophylactic anticoagulants.
Nanobiotix Transfers US Sponsorship of NANORAY-312 to Janssen, Anticipates Key Data Readouts
• Nanobiotix transferred the US sponsorship of the Phase 3 NANORAY-312 head and neck cancer study to Janssen, a key step for NBTXR3 regulatory submission.
• The company reported €53.2 million in cash and equivalents as of September 30, 2024, funding operations into Q4 2025.
• Updates on NBTXR3 in pancreatic and lung cancer studies with MD Anderson are expected in Q4 2024 and 1H 2025, respectively.
• An interim analysis for NANORAY-312 is anticipated in the first half of 2026, following required events and last patient recruitment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath